These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 32828269)

  • 1. SARS-CoV-2 E protein is a potential ion channel that can be inhibited by Gliclazide and Memantine.
    Singh Tomar PP; Arkin IT
    Biochem Biophys Res Commun; 2020 Sep; 530(1):10-14. PubMed ID: 32828269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches.
    Bhowmik D; Nandi R; Jagadeesan R; Kumar N; Prakash A; Kumar D
    Infect Genet Evol; 2020 Oct; 84():104451. PubMed ID: 32640381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fight against novel coronavirus: A perspective of medicinal chemists.
    Amin SA; Jha T
    Eur J Med Chem; 2020 Sep; 201():112559. PubMed ID: 32563814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2
    Weston S; Coleman CM; Haupt R; Logue J; Matthews K; Li Y; Reyes HM; Weiss SR; Frieman MB
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32817221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
    Gordon DE; Jang GM; Bouhaddou M; Xu J; Obernier K; White KM; O'Meara MJ; Rezelj VV; Guo JZ; Swaney DL; Tummino TA; Hüttenhain R; Kaake RM; Richards AL; Tutuncuoglu B; Foussard H; Batra J; Haas K; Modak M; Kim M; Haas P; Polacco BJ; Braberg H; Fabius JM; Eckhardt M; Soucheray M; Bennett MJ; Cakir M; McGregor MJ; Li Q; Meyer B; Roesch F; Vallet T; Mac Kain A; Miorin L; Moreno E; Naing ZZC; Zhou Y; Peng S; Shi Y; Zhang Z; Shen W; Kirby IT; Melnyk JE; Chorba JS; Lou K; Dai SA; Barrio-Hernandez I; Memon D; Hernandez-Armenta C; Lyu J; Mathy CJP; Perica T; Pilla KB; Ganesan SJ; Saltzberg DJ; Rakesh R; Liu X; Rosenthal SB; Calviello L; Venkataramanan S; Liboy-Lugo J; Lin Y; Huang XP; Liu Y; Wankowicz SA; Bohn M; Safari M; Ugur FS; Koh C; Savar NS; Tran QD; Shengjuler D; Fletcher SJ; O'Neal MC; Cai Y; Chang JCJ; Broadhurst DJ; Klippsten S; Sharp PP; Wenzell NA; Kuzuoglu-Ozturk D; Wang HY; Trenker R; Young JM; Cavero DA; Hiatt J; Roth TL; Rathore U; Subramanian A; Noack J; Hubert M; Stroud RM; Frankel AD; Rosenberg OS; Verba KA; Agard DA; Ott M; Emerman M; Jura N; von Zastrow M; Verdin E; Ashworth A; Schwartz O; d'Enfert C; Mukherjee S; Jacobson M; Malik HS; Fujimori DG; Ideker T; Craik CS; Floor SN; Fraser JS; Gross JD; Sali A; Roth BL; Ruggero D; Taunton J; Kortemme T; Beltrao P; Vignuzzi M; García-Sastre A; Shokat KM; Shoichet BK; Krogan NJ
    Nature; 2020 Jul; 583(7816):459-468. PubMed ID: 32353859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repurposing old drugs as antiviral agents for coronaviruses.
    Yang CW; Peng TT; Hsu HY; Lee YZ; Wu SH; Lin WH; Ke YY; Hsu TA; Yeh TK; Huang WZ; Lin JH; Sytwu HK; Chen CT; Lee SJ
    Biomed J; 2020 Aug; 43(4):368-374. PubMed ID: 32563698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockers of the SARS-CoV-2 3a Channel Identified by Targeted Drug Repurposing.
    Tomar PPS; Krugliak M; Arkin IT
    Viruses; 2021 Mar; 13(3):. PubMed ID: 33807095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing.
    Riva L; Yuan S; Yin X; Martin-Sancho L; Matsunaga N; Pache L; Burgstaller-Muehlbacher S; De Jesus PD; Teriete P; Hull MV; Chang MW; Chan JF; Cao J; Poon VK; Herbert KM; Cheng K; Nguyen TH; Rubanov A; Pu Y; Nguyen C; Choi A; Rathnasinghe R; Schotsaert M; Miorin L; Dejosez M; Zwaka TP; Sit KY; Martinez-Sobrido L; Liu WC; White KM; Chapman ME; Lendy EK; Glynne RJ; Albrecht R; Ruppin E; Mesecar AD; Johnson JR; Benner C; Sun R; Schultz PG; Su AI; García-Sastre A; Chatterjee AK; Yuen KY; Chanda SK
    Nature; 2020 Oct; 586(7827):113-119. PubMed ID: 32707573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
    Zhu Y; Yu D; Yan H; Chong H; He Y
    J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid repurposing of drugs for COVID-19.
    Guy RK; DiPaola RS; Romanelli F; Dutch RE
    Science; 2020 May; 368(6493):829-830. PubMed ID: 32385101
    [No Abstract]   [Full Text] [Related]  

  • 11.
    Sachdeva C; Wadhwa A; Kumari A; Hussain F; Jha P; Kaushik NK
    OMICS; 2020 Oct; 24(10):568-580. PubMed ID: 32757981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-SARS-CoV-2 Potential of Artemisinins In Vitro.
    Cao R; Hu H; Li Y; Wang X; Xu M; Liu J; Zhang H; Yan Y; Zhao L; Li W; Zhang T; Xiao D; Guo X; Li Y; Yang J; Hu Z; Wang M; Zhong W
    ACS Infect Dis; 2020 Sep; 6(9):2524-2531. PubMed ID: 32786284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
    Froggatt HM; Heaton BE; Heaton NS
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development.
    Aljabali AAA; Bakshi HA; Satija S; Metha M; Prasher P; Ennab RM; Chellappan DK; Gupta G; Negi P; Goyal R; Sharma A; Mishra V; Dureja H; Dua K; Tambuwala MM
    Pharm Nanotechnol; 2020; 8(4):323-353. PubMed ID: 32811406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug Repurposing Study Pinpoints Potential COVID-19 Antivirals.
    Abbasi J
    JAMA; 2020 Sep; 324(10):928. PubMed ID: 32897326
    [No Abstract]   [Full Text] [Related]  

  • 16. Prediction of potential inhibitors for RNA-dependent RNA polymerase of SARS-CoV-2 using comprehensive drug repurposing and molecular docking approach.
    Parvez MSA; Karim MA; Hasan M; Jaman J; Karim Z; Tahsin T; Hasan MN; Hosen MJ
    Int J Biol Macromol; 2020 Nov; 163():1787-1797. PubMed ID: 32950529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19).
    Yuan S; Chan CC; Chik KK; Tsang JO; Liang R; Cao J; Tang K; Cai JP; Ye ZW; Yin F; To KK; Chu H; Jin DY; Hung IF; Yuen KY; Chan JF
    Viruses; 2020 Jun; 12(6):. PubMed ID: 32532085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virtual screening, ADME/Tox predictions and the drug repurposing concept for future use of old drugs against the COVID-19.
    Hage-Melim LIDS; Federico LB; de Oliveira NKS; Francisco VCC; Correia LC; de Lima HB; Gomes SQ; Barcelos MP; Francischini IAG; da Silva CHTP
    Life Sci; 2020 Sep; 256():117963. PubMed ID: 32535080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 and COVID-19: What are our options? Where should we focus our attention on to find new drugs and strategies?
    Magro G
    Travel Med Infect Dis; 2020; 37():101685. PubMed ID: 32334088
    [No Abstract]   [Full Text] [Related]  

  • 20. Optimization Rules for SARS-CoV-2 M
    Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.